ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Autoantibody(ies)"

  • Abstract Number: 1475 • ACR Convergence 2023

    Retrospective Study of Obesity on Clinical and Immunological Features in Systemic Lupus Erythematosus Using AI Software Deep 6 and EPIC Slicer Dicer

    Shivani Shah1, chandana keshavamurthy1, Samantha Ahrens1, Douglas Reeves1, William Davis1, Robert Quinet1, Jerald Zakam1, Samina Hayat2, Teresa Leeth2, Sarwat Umer3, Sulman Hasan2, Maria Latsis2, Xin Zhang1 and Gitanjali Lobo4, 1Ochsner Health, New Orleans, LA, 2Louisiana State University, Shreveport, LA, 3LSU Health Shreveport, Shreveport, LA, 4Ochsner Clinic Foundation, Baton Rouge, LA

    Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by autoantibodies and systemic inflammation, affecting multiple organs especially kidney. Environmental factors, genetic predisposition,…
  • Abstract Number: 1949 • ACR Convergence 2023

    Relapse of Rapidly Progressive Interstitial Lung Disease in Patients with Anti-Melanoma Differentiation-Associated Gene 5 Autoantibody-Positive Dermatomyositis

    Noriko Sasaki, Toshiki Ohisa, Akira Ishii, Mai Sugiyama, Yuichiro Ota, Chiho Yamada and Shinji Sato, Tokai university School of Medicine, Isehara, Japan

    Background/Purpose: Autoantibodies to Melanoma Differentiation-Associated Gene 5 (MDA5) are found specifically in patients with dermatomyositis (DM). Their presence is closely associated with rapidly progressive interstitial…
  • Abstract Number: 2466 • ACR Convergence 2023

    Monoclonal Anti-MDA5 Autoantibodies Derived from a Patient with Dermatomyositis Target the Hel2i Domain of the MDA5 Protein

    Eveline Van Gompel1, Ragnhild Stålesen2, Caroline Grönwall2, Annika van Vollenhoven2, Lena Israelsson2, Ingrid Lundberg3, Vivianne Malmström2, Karine Chemin4 and Vijay Joshua2, 1Karolinska Institutet - KU Leuven, Leuven, Belgium, 2Karolinska Institutet, Stockholm, Sweden, 3Division of Rheumatology, Department of Medicine, Karolinska Institutet; Department of Gastroenterology, Dermatotology, Rhematology, Karolinska Universitetssjukhuset, Stockholm, Sweden, 4Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: The strong clinical association between the anti-MDA5 autoantibodies and the development of severe lung disease in patients with dermatomyositis (DM) suggests an active role…
  • Abstract Number: 067 • 2023 Pediatric Rheumatology Symposium

    Clinical and Demographic Characteristics of Children with Anti-NMDAR Encephalitis

    Yike Jiang, Alexander Sandweiss, Timothy Erickson, Eyal Muscal and Kristy Murray, Baylor College of Medicine, Houston, TX

    Background/Purpose: The discovery of anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis heralded a new class of neuropsychiatric illnesses mediated by autoantibodies, known collectively as autoimmune encephalitis. The clinical…
  • Abstract Number: 114 • 2023 Pediatric Rheumatology Symposium

    Clinical Significance of SSA and SSB Antibodies in Pediatric SLE Patients: A Single Center Cohort

    Yiressy Pina1, Dawn Janysek1, Danielle Guffey2, Maria Pereira Palacios3 and Marietta De Guzman1, 1Baylor College of Medicine, Texas Children's Hospital, Houston, TX, 2Baylor College of Medicine, Houston, TX, 3Baylor College of Medicine, Texas Children's Hospital, Houston, TX

    Background/Purpose: Anti-nuclear antibodies (ANA) are important in the diagnosis of Systemic Lupus Erythematosus (SLE). Of the disease specific ANAs, anti-dsDNA and anti- Smith antibodies carry…
  • Abstract Number: 116 • 2023 Pediatric Rheumatology Symposium

    Clinical Significance of Anti-Scl-70 Antibodies in Pediatric Lupus Patients: A Single Center Cohort

    Dawn Janysek1, Yiressy Pina2, Danielle Guffey3 and Marietta De Guzman1, 1Baylor College of Medicine, Texas Children's Hospital, Houston, TX, 2Baylor College of Medicine, Texas Children's Hospital, Houston, TX, 3Baylor College of Medicine, Houston, TX

    Background/Purpose: Production of autoantibodies is a hallmark of SLE, with ANAs as a required diagnostic feature and anti-dsDNA and anti-Smith antibodies being disease-specific. Anti-Scl-70 antibodies…
  • Abstract Number: L13 • ACR Convergence 2022

    Fetal Cardiac Targets Identify the Autoantibodies Associated with Congenital Heart Block

    Stephanie Benjamin1, Lisa Vi2, Diptendu Chatterjee1, Edgar Jaeggi1, Marie Wahren-Herlenius3, Amelia Ruffatti4, Linda Hiraki5, Michelle Lohbihler2, Lusia Sepiashvili1, Carl Laskin6, Meena Fatah1, Daniela Dominguez5, Lawrence Ng5, Anthony Gramolini2, Vincent Christoffels7, Stephanie Protze2 and Robert Hamilton8, 1Hospital for Sick Children, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, 4Universitå di Padova, Padova, Italy, 5The Hospital for Sick Children, Toronto, ON, Canada, 6Mt. Sinai Hospital/University of Toronto, Toronto, ON, Canada, 7Amsterdam UMC, Amsterdam, Zuid-Holland, Netherlands, 8Hospital for Sick Children, Markham, ON, Canada

    Background/Purpose: Autoimmune congenital heart block (CHB+) affects the fetus of mothers with anti-Ro antibodies. Anti-Ro (Ro+) antibodies (Abs) are usually present in maternal sera when…
  • Abstract Number: 0035 • ACR Convergence 2022

    Anti-Peroxiredoxin 6 and Anti- Myosin Light Polypeptide 6 Autoantibodies with Interstitial Lung Disease and Severe Disease in Juvenile Dermatomyositis

    Rie Karasawa1, James Jarvis2, Toshiko Sato1, Megumi Tanaka1, Terrance P O'Hanlon3, Payam Noroozi-Farhadi4, Willy A. Flegel5, Kazuo Yudoh1 and Lisa G Rider3, 1Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan, 2Department of Pediatrics, University at Buffalo Clinical and Translational Research Center, Buffalo, NY, 3Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health, Bethesda, MD, 4NIEHS, NIH, Garrett Park, MD, 5NIH, Garrett Park, MD

    Background/Purpose: Juvenile idiopathic arthritis (JIA) and juvenile dermatomyositis (JDM) are among the most common forms of inflammatory rheumatic diseases in children. Anti-endothelial cell antibodies (AECA)…
  • Abstract Number: 0639 • ACR Convergence 2022

    Association of Gut Microbiome Streptococcus, Health Status, Cytokines, and HLA Class in Anti-Ro+ Mothers of Children with Neonatal Lupus: Insights into Progression of Clinical Autoimmunity

    Robert Clancy1, Joel Guthridge2, Miranda Marion3, Hannah Ainsworth4, Marci Beel2, Christina Firl5, Nicola Fraser6, Nour Hachemian5, Timothy Howard4, Peter Izmirly1, Mala Masson7, Melissa Munroe2, Jill Buyon1, Judith James2 and Carl Langefeld8, 1NYU Grossman School of Medicine, New York, NY, 2Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Wake Forest University, Winston-Salem, NC, 4Wake Forest School of Medicine, Winston-Salem, NC, 5NYU Langone Health, New York, NY, 6NYU School of Medicine, New York, NY, 7NYU Langone Medical Center- Division of Rheumatology, New York, NY, 8Wake Forest School of Medicine, Winston Salem, NC

    Background/Purpose: High titer anti-Ro+ mothers of children with neonatal lupus (NL), often completely asymptomatic, offer a unique opportunity to uncover insights into permissive and protective…
  • Abstract Number: 0910 • ACR Convergence 2022

    Rheumatoid Arthritis Associated Interstitial Lung Disease: The Role of Non-Criteria Autoantibodies

    Albert Pérez-Isidro1, Raul Castellanos-Moreira1, Juan Camilo Sarmiento-Monroy2, Noemi de Moner1, Maresa Grundhuber3, Odette Vinas1, Raimon Sanmarti2 and Estibaliz Ruiz-Ortiz1, 1Hospital Clinic of Barcelona, Barcelona, Spain, 2Hospital Clínic de Barcelona, Barcelona, Spain, 3Thermo Fisher Scientific, Freiburg, Germany

    Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic joint inflammation. RA-associated interstitial lung disease (ILD) is the most frequent and severe extra-articular…
  • Abstract Number: 1442 • ACR Convergence 2022

    Role of Platelet-bound Complement Activation Product (PC4d) in Predicting Risk of Future Thrombotic Events in Systemic Lupus Erythematosus

    Anca Askanase1, John Conklin2, Michelle Petri3, Vasileios Kyttaris4, Yevgeniya Gartshteyn5, Wei Tang1, Anja Kammesheidt6 and Roberta Alexander2, 1Columbia University Medical Center, New York, NY, 2Exagen, Inc., Vista, CA, 3Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, 4Beth Israel Deaconess Medical Center, Boston, MA, 5Columbia University Medical Center, Glen Rock, NJ, 6self, Laguna Beach, CA

    Background/Purpose: Platelet-bound complement activation products (PC4d) are associated with a history of thrombosis in systemic lupus erythematosus (SLE) (Gartshteyn al., 2021; Petri et al., 2017).…
  • Abstract Number: 1874 • ACR Convergence 2022

    Autoantibodies Are Common in Patients with Idiopathic Interstitial Lung Disease Suggesting a High Prevalence of Undiagnosed Autoimmune Connective Tissue Disease

    Sarah Tansley1, Caroline Cotton2, Fionnuala McMorrow1, Hui Lu1, Aravinthan Loganathan1, Zoe Betteridge1, Robert New3, Lisa Spencer4, Neil McHugh1 and Robert Cooper4, 1University of Bath, Bath, United Kingdom, 2Liverpool University Hospital, Liverpool, United Kingdom, 3NCA, Manchester, 4University of Liverpool, Liverpool

    Background/Purpose: In some patients, interstitial lung disease (ILD) may be the dominant or even sole overt manifestation of an otherwise unrecognised autoimmune connective tissue disease…
  • Abstract Number: 2240 • ACR Convergence 2022

    Autoimmunity Against Melanoma Differentiation-Associated Protein 5 Advances Acute Lung Injury to Interstitial Lung Disease in Mice

    Yuki Ichimura1, Risa Konishi1, Toshifumi Nomura2, Manabu Fujimoto3 and Naoko Okiyama1, 1Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan, 2University of Tsukuba, Tsukuba, Ibaraki, Japan, 3Osaka University, Suita, Japan

    Background/Purpose: Anti-melanoma differentiation-associated protein 5 (MDA5) antibody-positive dermatomyositis (DM) is characterized by amyopathic DM with interstitial lung disease (ILD). Patients with anti-MDA5 antibody-associated DM sometimes…
  • Abstract Number: 0037 • ACR Convergence 2022

    Dual (and Dueling) Fibroblast Differentiation Is Integral to the Pathogenesis of Anti-Ro Mediated Congenital Heart Block and Provides a Novel Biomarker of Severity

    Christina Firl1, Robert Clancy2, Bettina Cuneo3, Nicola Fraser4, Marc Halushka5, Mala Masson6, Amit Saxena1 and Jill Buyon2, 1NYU Langone Health, New York, NY, 2NYU Grossman School of Medicine, New York, NY, 3University of Colorado School of Medicine, Aurora, CO, 4NYU School of Medicine, New York, NY, 5Johns Hopkins Medicine, Baltimore, MD, 6NYU Langone Medical Center- Division of Rheumatology, New York, NY

    Background/Purpose: Fibroblast heterogeneity may provide critical insights into autoimmune mediated tissue damage. Transdifferentiation to a scarring myofibroblast is characterized by expression of alpha-Smooth Muscle Actin…
  • Abstract Number: 0663 • ACR Convergence 2022

    Anti-Erythrocyte Antibodies in Childhood Onset Systemic Lupus Erythematosus

    Lauren Robinson1, Zurong Wan2, Preetha Balasubramanian3, Juan Rodriguez Alcazar3, Lynnette Walters4, Jeanine Baisch2, karen onel5, Tracey Wright6, Virginia Pascual3 and Simone Caielli3, 1Hospital for Special Surgery/New York Presbyterian-Weill Cornell, New York, NY, 2Weill Cornell Medicine, New York, NY, 3Weill Cornell Medical College, New York, NY, 4Scottish Rite Hospital for Children, Allen, TX, 5Hospital for Special Surgery, New York, NY, 6UT Southwestern, Plano, TX

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a disease characterized by the presence of auto-antibodies, immune complex deposition, and a robust type 1 interferon signature. It…
  • « Previous Page
  • 1
  • …
  • 20
  • 21
  • 22
  • 23
  • 24
  • …
  • 37
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology